NCT07915258
Becotatug Vedotin Plus Pucotenlimab in Locally Advanced Head and Neck Squamous Cell Carcinoma With Suboptimal Response to Induction Immunochemotherapy
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Objective Response Rate (ORR)
Timeframe: From baseline to preoperative tumor assessment after two treatment cycles (approximately 6-10 weeks after the first dose)
Secondary (9)
Pathological Complete Response Rate (pCR)
Major Pathological Response Rate (MPR)
R0 Resection Rate
Organ Preservation Rate
Incidence of Adverse Events (AEs)
Show 4 moreShow less
Event-Free Survival (EFS) Rate at 1 and 2 Years
Disease-Free Survival (DFS) Rate at 1 and 2 Years
Overall Survival (OS) Rate at 1 and 2 Years
Clinicopathological Downstaging Rate
Arms and interventions
Adaptive Neoadjuvant TherapyExperimental
Patients with locally advanced, resectable head and neck squamous cell carcinoma who have achieved stable disease or progressive disease following induction immunochemotherapy will receive becotatug vedotin (MRG003) at 2.0 mg/kg and pucotenlimab (HX008) at 200 mg intravenously every three weeks for two cycles, followed by curative-intent surgery and standard postoperative treatment as clinically indicated.
Drugs: Becotatug Vedotin (MRG003), Pucotenlimab
Sites
4 sites in 1 country